Target
ACVR1
11 abstracts
Abstract
Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion.Org: Washington University School of Medicine in St. Louis, The John Theurer Cancer Center at Hackensack Meridian Health, Wroclaw Medical University, Sobi Inc., Cleveland Clinic Taussig Cancer Institute,
Abstract
Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial.Org: Princess Margaret Cancer Centre, University Health Network, Cleveland Clinic Taussig Cancer Institute, University of Florence, AOUC, Clinical Investigation Center,
Abstract
Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.Org: Istituto di Ematologia s. Orsola-Malpighi,
Abstract
Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib in the United States.Org: Sobi Inc., IntegraConnect, PrecisionQ, Leukemia Service,
Abstract
Association between ferritin, hemoglobin, and anemia response in jaktinib-treated patients with myelofibrosis: A post-hoc analysis of the ZGJAK006 study.Org: The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Jiangsu Provincial People’s Hospital, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalize, Shanghai Jiaotong University Medical School,
Abstract
Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.Org: Memorial Sloan Kettering Cancer Center, Guy’s and St Thomas’ NHS Trust, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”, Istituto di Ematologia "Seràgnoli", Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,
Abstract
Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2).Org: Wake Forest University School of Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna - Istituto di Ematologia “Seràgnoli”, Istituto di Ematologia Seràgnoli, University of Texas MD Anderson Cancer Center, Department of Leukemia, The University of Texas MD Anderson Cancer Center,
Abstract
Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University Medical Center Hamburg-Eppendorf, Princess Margaret Cancer Centre, University Health Network, University College London Hospitals NHS Foundation Trust,
Abstract
Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF).Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy, Wake Forest University School of Medicine, Winston-Salem, NC, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, Analysis Group, Boston, MA, GlaxoSmithKline USA, Collegeville, PA, GlaxoSmithKline, Philadelphia, PA, GlaxoSmithKline Pharmaceuticals, Collegeville, PA, GlaxoSmithKline, Reading, United Kingdom, Analysis Group, Inc, Boston, MA,
Abstract
Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, College of Medicine, University of the Philippines - Manila, Zhejiang University, Hangzhou, China, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group,